CSTB Rabbit Polyclonal Antibody

CAT#: TA367028

CSTB rabbit polyclonal antibody

Product Images

Immunohistochemistry of paraffin-embedded Human cervical cancer tissue using TA367028 (CSTB Antibody) at dilution 1/30 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human cervical cancer tissue using TA367028 (CSTB Antibody) at dilution 1/30, treated with synthetic peptide. (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human liver cancer tissue using TA367028 (CSTB Antibody) at dilution 1/30 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human liver cancer tissue using TA367028 (CSTB Antibody) at dilution 1/30, treated with synthetic peptide. (Original magnification: ×200)

Specifications

Product Data

• Applications: IHC
• Recommended Dilution: IHC: 50-200
  Positive control: Human cervical cancer
  Predicted cell location: Cytoplasm and Nucleus
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Synthetic peptide of human CSTB
• Formulation: pH7.4 PBS, 0.05% NaN3, 40% Glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C.
• Stability: 1 year
• Database Link:
  UniProt ID P04080
• Background: The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and kininogens. This gene encodes a stefin that functions as an intracellular thiol protease inhibitor. The protein is able to form a dimer stabilized by noncovalent forces, inhibiting papain and cathepsins l, h and b. The protein is thought to play a role in protecting against the proteases leaking from lysosomes. Evidence indicates that mutations in this gene are responsible for the primary defects in patients with progressive myoclonic epilepsy (EPM1).